Ranibizumab for the treatment of expression of inflammatory factors in patients of exudative age-related macular degeneration

Objective To investigate ranibizumab intravitreal injection for the treatment of expression of inflammatory factors in aqueous humor in patients of exudative age-related macular degeneration (AMD). Methods The data of 56 eyes of 56 patients with wet AMD treated with ranibizumab from Jan. 2015 to Dec. 2016 were retrospectively analyzed. The followed-up time was 1 month after the treatment. Results The visual acuity were improved in 44 eyes (78.57%). After treatment, IOP, central macular thickness (CMT) and choroidal neovascularization (CNV) area decreased significantly, TNF-α and IL-6 in aqueous humor decreased significantly, and the differences were statistically significant (P=0.000). There were positive correlations between IOP, CMT, CNV, TNF-α and IL-6 (P=0.000). IOP and TNF-α were independent correlation factors of CMT (P=0.000, 0.001). Conclusion Ranibizumab for the treatment of wet AMD is effective. The inhibition effect on TNF-α is directly related to the control effect on CMT. Key words: Degeneration, macular, age-related, exudative; Ranibizumab; Factors, inflammatory, aqueous humor